In The News
In The News
The Urology Group Introduces Cutting Edge
Prostate Biopsy Option with 3D MRI/Ultrasound Fusion Technology
Leesburg, VA 5/21/18 – Targeted MRI/Ultrasound Fusion biopsy is the latest technology available in the detection and management of prostate cancer and The Urology Group is proud to offer this new standard of care.
Historically, finding the exact location of cancer in a prostate gland has been a challenge. Conventional TRUS prostate biopsy techniques are referred to as “blind” biopsies since physicians typically cannot easily view the specific location of any abnormal tissue. Now, using the revolutionary Artemis 3D imaging and navigation system, physicians are able to better identify and more accurately biopsy suspicious prostate cancer areas.
The MRI/Ultrasound Fusion (or MR/US Fusion) targeted biopsy procedure starts by using pre-exam MRI prostate images. These images are then fused with real-time ultrasound images to create a detailed 3D high-definition map of the prostate. This allows the physician to accurately target any visible lesions during the biopsy.
Patients recommended for this procedure are men who, typically, have elevated and/or rising prostate-specific antigen (PSA) levels despite negative ultrasound-guided biopsy or those with a clinical concern for prostate cancer.
According to the American Cancer Society, prostate cancer is the second most common cancer in men after skin cancer, and one in seven men will be diagnosed in his lifetime. Prostate cancer can be a serious disease, but with early detection, most men have a 5 year survival rate of 90%.
The Urology Group introduction of the MRI/Ultrasound Fusion Prostate biopsy system is the latest breakthrough option in providing patients with improved diagnosis and accuracy in the detection and treatment of prostate cancer.
Contact The Urology Group at (703.724.1195) to learn more and to schedule your prostate cancer screening.